Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer

被引:43
|
作者
Weitzel, Jeffrey N. [1 ,2 ]
Neuhausen, Susan L. [3 ]
Adamson, Aaron [3 ]
Tao, Shu [4 ]
Ricker, Charite [2 ,5 ]
Maoz, Asaf [5 ]
Rosenblatt, Margalit [6 ]
Nehoray, Bita [1 ,2 ]
Sand, Sharon [1 ,2 ]
Steele, Linda [3 ]
Unzeitig, Gary [2 ,7 ]
Feldman, Nancy [2 ]
Blanco, Amie M. [6 ]
Hu, Donglei [8 ]
Huntsman, Scott [8 ]
Castillo, Danielle [1 ,2 ]
Haiman, Christopher [10 ]
Slavin, Thomas [1 ,2 ]
Ziv, Elad [6 ,8 ,9 ]
机构
[1] City Hope Natl Med Ctr, Div Clin Canc Genom, 1500 East Duarte Rd, Duarte, CA 91010 USA
[2] Clin Canc Genom Community Res Network, Los Angeles, CA USA
[3] City Hope Natl Med Ctr, Div Biomarkers Early Detect & Prevent, Duarte, CA USA
[4] City Hope Natl Med Ctr, Integrat Genom Core, Duarte, CA USA
[5] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[7] Gary Unzeitig MD Off, Laredo, TX USA
[8] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA USA
[9] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA
[10] Univ Southern Calif, Keck Sch Med, Ctr Genet Epidemiol, Dept Prevent Med, Los Angeles, CA 90033 USA
基金
美国国家卫生研究院;
关键词
breast cancer; checkpoint kinase 2 (CHEK2); disparities; Hispanics; ovarian cancer; partner and localizer of BRCA2 (PALB2); whole-exome sequencing; RISK ASSESSMENT; MUTATIONS; PREVALENCE; GENETICS; OVARIAN; GENOMICS; PANEL; ASSOCIATION; STANDARDS; ANCESTRY;
D O I
10.1002/cncr.32083
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Breast cancer (BC) is the most common cancer and related cause of mortality among Hispanics, yet susceptibility has been understudied. BRCA1 and BRCA2 (BRCA) mutations explain less than one-half of hereditary BC, and the proportion associated with other BC susceptibility genes is unknown. Methods Germline DNA from 1054 BRCA-mutation-negative Hispanic women with hereditary BC (BC diagnosed at age <51 years, bilateral BC, breast and ovarian cancer, or BC diagnosed at ages 51-70 years with >= 2 first-degree or second-degree relatives who had BC diagnosed at age <70 years), 312 local controls, and 887 multiethnic cohort controls was sequenced and analyzed for 12 known and suspected, high-penetrance and moderate-penetrance cancer susceptibility genes (ataxia telangiectasia mutated [ATM], breast cancer 1 interacting protein C-terminal helicase 1 [BRIP1], cadherin 1 [CDH1], checkpoint kinase 2 [CHEK2], nibrin [NBN], neurofibromatosis type 1 [NF1], partner and localizer of BRCA2 [PALB2], phosphatase and tensin homolog [PTEN], RAD51 paralog 3 [RAD51C], RAD51D, serine/threonine kinase 11 [STK11], and TP53). Results Forty-nine (4.6%) pathogenic or likely pathogenic variants (PVs) in 47 of 1054 participants (4.5%), including 21 truncating frameshift, 20 missense, 5 nonsense, and 4 splice variants, were identified in CHEK2 (n = 20), PALB2 (n = 18), ATM (n = 5), TP53 (n = 3), BRIP1 (n = 2), and CDH1 and NF1 (both n = 1) and none were identified in NBN, PTEN, STK11, RAD51C, or RAD51D. Nine participants carried the PALB2 c.2167_2168del PV (0.85%), and 14 carried the CHEK2 c.707T>C PV (1.32%). Conclusions Of 1054 BRCA-negative, high-risk Hispanic women, 4.5% carried a PV in a cancer susceptibility gene, increasing understanding of hereditary BC in this population. Recurrent PVs in PALB2 and CHEK2 represented 47% (23 of 49) of the total, suggesting a founder effect. Accurate classification of variants was enabled by carefully controlling for ancestry and the increased identification of at-risk Hispanics for screening and prevention.
引用
收藏
页码:2829 / 2836
页数:8
相关论文
共 50 条
  • [1] Germline mutations in ATM, CHEK2, and other known/potential breast cancer susceptibility genes among BRCA-negative Uruguayan patients with breast cancer.
    Delgado, Lucia Beatriz
    Cayota, Alfonso
    Artagaveytia, Nora
    Olivera, Noelia Silveyra
    Gulaute, Sebastian Francisco Ximenez
    Manrique, Gonzalo
    Simoes, Camila
    Spangenberg, Lucia
    Naya, Hugo
    Sanguinetti, Julia
    Blanco, Valentina
    Camejo, Natalia
    Castillo, Cecilia
    Cataldi, Sandra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Factors that differentiate cancer risk management decisions among females with pathogenic/likely pathogenic variants in PALB2, CHEK2, and ATM
    Dean, Marleah
    Tezak, Ann L.
    Johnson, Sabrina
    Weidner, Anne
    Almanza, Deanna
    Pal, Tuya
    Cragun, Deborah L.
    GENETICS IN MEDICINE, 2023, 25 (11)
  • [3] Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
    Yadav, Siddhartha
    Boddicker, Nicholas J.
    Na, Jie
    Polley, Eric C.
    Hu, Chunling
    Hart, Steven N.
    Gnanaolivu, Rohan D.
    Larson, Nicole
    Holtegaard, Susan
    Huang, Huaizhi
    Dunn, Carolyn A.
    Teras, Lauren R.
    Patel, Alpa V.
    Lacey, James V.
    Neuhausen, Susan L.
    Martinez, Elena
    Haiman, Christopher
    Chen, Fei
    Ruddy, Kathryn J.
    Olson, Janet E.
    John, Esther M.
    Kurian, Allison W.
    Sandler, Dale P.
    O'Brien, Katie M.
    Taylor, Jack A.
    Weinberg, Clarice R.
    Anton-Culver, Hoda
    Ziogas, Argyrios
    Zirpoli, Gary
    Goldgar, David E.
    Palmer, Julie R.
    Domchek, Susan M.
    Weitzel, Jeffrey N.
    Nathanson, Katherine L.
    Kraft, Peter
    Couch, Fergus J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (09) : 1703 - +
  • [4] Ki-67 Expression in Breast Cancer associated with ATM, BRCA1, BRCA2, CHEK2 and PALB2 Pathogenic Variants
    Scheel, Robert
    Choong, Grace
    Rao, Tara
    Boddicker, Nicholas
    Hu, Chunling
    Na, Jie
    Kaggal, Vinod
    Murphy, Sean
    Giridhar, Karthik
    Yasir, Saba
    Goetz, Matthew
    Couch, Fergus
    Yadav, Siddhartha
    CANCER RESEARCH, 2024, 84 (09)
  • [5] Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants A Comparative Modeling Analysis
    Lowry, Kathryn P.
    Geuzinge, H. Amarens
    Stout, Natasha K.
    Alagoz, Oguzhan
    Hampton, John
    Kerlikowske, Karla
    de Koning, Harry J.
    Miglioretti, Diana L.
    van Ravesteyn, Nicolien T.
    Schechter, Clyde
    Sprague, Brian L.
    Tosteson, Anna N. A.
    Trentham-Dietz, Amy
    Weaver, Donald
    Yaffe, Martin J.
    Yeh, Jennifer M.
    Couch, Fergus J.
    Hu, Chunling
    Kraft, Peter
    Polley, Eric C.
    Mandelblatt, Jeanne S.
    Kurian, Allison W.
    Robson, Mark E.
    JAMA ONCOLOGY, 2022, 8 (04) : 587 - 596
  • [6] Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis.
    Lowry, Kathryn P.
    Geuzinge, H. Amarens
    Stout, Natasha K.
    Alagoz, Oguzhan
    Hampton, John M.
    Kerlikowske, Karla
    Miglioretti, Diana L.
    Schecter, Clyde
    Sprague, Brian L.
    Trentham-Dietz, Amy
    Tosteson, Anna N. A.
    Van Ravesteyn, Nicolien
    Yaffe, Martin
    Yeh, Jennifer
    Couch, Fergus
    Kraft, Peter
    Polley, Eric
    Mandelblatt, Jeanne S.
    Kurian, Allison W.
    Robson, Mark E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Population-based Estimates of contralateral Breast Cancer Risk among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
    Yadav, Siddhartha
    Boddicker, Nicholas J.
    Na, Jie
    Polley, Eric C.
    Hu, Chunling
    Hart, Steven N.
    Gnanaolivu, Rohan D.
    Larson, Nicole
    Dunn, Carolyn
    Holtegaard, Susan
    Huang, Huaizhi
    Teras, Lauren R.
    Patel, Alpa V.
    Lacey, James V., Jr.
    Neuhausen, Susan
    Bernstein, Leslie
    Martinez, Elena
    Haiman, Christopher
    Chen, Fei
    Ruddy, Kathryn
    Olson, Janet
    John, Esther
    Kurian, Allison W.
    Sandler, Dale P.
    O'Brien, Katie M.
    Taylor, Jack A.
    Weinberg, Clarice R.
    Anton-Culver, Hoda
    Ziogas, Argyrios
    Zirpoli, Gary R.
    Goldgar, David E.
    Nathanson, Katherine L.
    Domchek, Susan
    Palmer, Julie R.
    Weitzel, Jeffrey
    Kraft, Peter
    Couch, Fergus J.
    CANCER RESEARCH, 2023, 83 (05)
  • [8] Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.
    Scott, Danika
    Kingham, Kerry
    Hodan, Rachel
    Ma, Cindy
    Mills, Meredith
    Ford, James M.
    Kurian, Allison W.
    Telli, Melinda L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Real-world clinical characteristics and management of breast cancer in patients with germline pathogenic variants in ATM, CHEK2 and PALB2
    Brzeskiewicz, Laura
    Roscow, Breanna
    Beeks, April
    Kunz, Barb
    Ratzel, Sarah
    Slavin, Thomas
    Cummings, Shelly
    Tedesco, Karen
    Reid, Robert
    GENETICS IN MEDICINE, 2022, 24 (03) : S34 - S34
  • [10] Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort
    McInerney, N. M.
    Miller, N.
    Rowan, A.
    Colleran, G.
    Barclay, E.
    Curran, C.
    Kerin, M. J.
    Tomlinson, I. P.
    Sawyer, E.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (01) : 203 - 210